Cargando…
SARS-CoV-2 Omicron variant: recent progress and future perspectives
Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of which is the Omicron variant (B.1.1.529). The Omicron variant is the most mutated SARS-CoV-2 variant, and its high transm...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047469/ https://www.ncbi.nlm.nih.gov/pubmed/35484110 http://dx.doi.org/10.1038/s41392-022-00997-x |
_version_ | 1784695733270609920 |
---|---|
author | Fan, Yao Li, Xiang Zhang, Lei Wan, Shu Zhang, Long Zhou, Fangfang |
author_facet | Fan, Yao Li, Xiang Zhang, Lei Wan, Shu Zhang, Long Zhou, Fangfang |
author_sort | Fan, Yao |
collection | PubMed |
description | Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of which is the Omicron variant (B.1.1.529). The Omicron variant is the most mutated SARS-CoV-2 variant, and its high transmissibility and immune evasion ability have raised global concerns. Owing to its enhanced transmissibility, Omicron has rapidly replaced Delta as the dominant variant in several regions. However, recent studies have shown that the Omicron variant exhibits reduced pathogenicity due to altered cell tropism. In addition, Omicron exhibits significant resistance to the neutralizing activity of vaccines, convalescent serum, and most antibody therapies. In the present review, recent advances in the molecular and clinical characteristics of the infectivity, pathogenicity, and immune evasion of Omicron variant was summarized, and potential therapeutic applications in response to Omicron infection were discussed. Furthermore, we highlighted potential response to future waves and strategies to end the pandemic. |
format | Online Article Text |
id | pubmed-9047469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90474692022-04-28 SARS-CoV-2 Omicron variant: recent progress and future perspectives Fan, Yao Li, Xiang Zhang, Lei Wan, Shu Zhang, Long Zhou, Fangfang Signal Transduct Target Ther Review Article Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of which is the Omicron variant (B.1.1.529). The Omicron variant is the most mutated SARS-CoV-2 variant, and its high transmissibility and immune evasion ability have raised global concerns. Owing to its enhanced transmissibility, Omicron has rapidly replaced Delta as the dominant variant in several regions. However, recent studies have shown that the Omicron variant exhibits reduced pathogenicity due to altered cell tropism. In addition, Omicron exhibits significant resistance to the neutralizing activity of vaccines, convalescent serum, and most antibody therapies. In the present review, recent advances in the molecular and clinical characteristics of the infectivity, pathogenicity, and immune evasion of Omicron variant was summarized, and potential therapeutic applications in response to Omicron infection were discussed. Furthermore, we highlighted potential response to future waves and strategies to end the pandemic. Nature Publishing Group UK 2022-04-28 /pmc/articles/PMC9047469/ /pubmed/35484110 http://dx.doi.org/10.1038/s41392-022-00997-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Fan, Yao Li, Xiang Zhang, Lei Wan, Shu Zhang, Long Zhou, Fangfang SARS-CoV-2 Omicron variant: recent progress and future perspectives |
title | SARS-CoV-2 Omicron variant: recent progress and future perspectives |
title_full | SARS-CoV-2 Omicron variant: recent progress and future perspectives |
title_fullStr | SARS-CoV-2 Omicron variant: recent progress and future perspectives |
title_full_unstemmed | SARS-CoV-2 Omicron variant: recent progress and future perspectives |
title_short | SARS-CoV-2 Omicron variant: recent progress and future perspectives |
title_sort | sars-cov-2 omicron variant: recent progress and future perspectives |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047469/ https://www.ncbi.nlm.nih.gov/pubmed/35484110 http://dx.doi.org/10.1038/s41392-022-00997-x |
work_keys_str_mv | AT fanyao sarscov2omicronvariantrecentprogressandfutureperspectives AT lixiang sarscov2omicronvariantrecentprogressandfutureperspectives AT zhanglei sarscov2omicronvariantrecentprogressandfutureperspectives AT wanshu sarscov2omicronvariantrecentprogressandfutureperspectives AT zhanglong sarscov2omicronvariantrecentprogressandfutureperspectives AT zhoufangfang sarscov2omicronvariantrecentprogressandfutureperspectives |